Results 131 to 140 of about 8,234,457 (404)

Quantitative performance assessment of Ultivue multiplex panels in formalin-fixed, paraffin-embedded human and murine tumor specimens

open access: yesScientific Reports
We present a rigorous validation strategy to evaluate the performance of Ultivue multiplex immunofluorescence panels. We have quantified the accuracy and precision of four different multiplex panels (three human and one mouse) in tumor specimens with ...
Sripad Ram   +5 more
doaj   +1 more source

Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.gov registry

open access: yesBMJ Open, 2016
Objective Phase IV trials are often used to investigate drug safety after approval. However, little is known about the characteristics of contemporary phase IV clinical trials and whether these studies are of sufficient quality to advance medical ...
Xin-ji Zhang   +5 more
semanticscholar   +1 more source

Drug tolerability versus drug safety

open access: yesJournal of Dermatological Treatment, 2023
Stuti Prajapati   +2 more
openaire   +3 more sources

Drug Possession Arrests Reported in Alaska, 1986–2017 [PDF]

open access: yes, 2018
Underlying data is available in both Excel and PDF format. (Download below.)This fact sheet presents data on drug sale possession arrests reported by Alaska law enforcement agencies for the 32-year period 1986 to 2017. Overall, the drug possession arrest
Ervin, Benjamin
core  

What is the epidemiology of medication errors, error-related adverse events and risk factors for errors in adults managed in community care contexts? A systematic review of the international literature [PDF]

open access: yes, 2018
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.Objective To investigate the epidemiology of medication errors and ...
Aljadhey, Hisham   +6 more
core   +3 more sources

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Exploring BSEP Inhibition-Mediated Toxicity with a Mechanistic Model of Drug-Induced Liver Injury

open access: yesFrontiers in Pharmacology, 2014
Inhibition of the bile salt export pump (BSEP) has been linked to incidence of drug-induced liver injury (DILI), presumably by the accumulation of toxic bile acids in the liver.
Jeffrey L Woodhead   +6 more
doaj   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

open access: yesMolecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli   +7 more
wiley   +1 more source

kurz und kn@pp news : Nr. 11 [engl. Fassung] [PDF]

open access: yes, 2008
* Prize for excellent teaching * Drug prescription safety and renal failure * Prof. Gerlach on the Health Research Council of the German Ministry for Education and Research * Health in Old Age * DEGAM against IGeLn * A Meeting of

core  

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy